Geode Capital Management »

Rapport Therapeutics shares owned by Geode Capital Management

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Geode Capital Management from 13F filings

Historical chart of Geode Capital Management investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Geode Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Geode Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $4.1M 202k 20.49

More positions owned by Geode Capital Management

Apple (AAPL)
Microsoft Corporation (MSFT)
NVIDIA Corporation (NVDA)
Amazon (AMZN)
Meta Platforms Inc-class A Cl A (META)
Alphabet Inc-cl A Cap Stk Cl A (GOOGL)
Alphabet Inc-cl C Cap Stk Cl C (GOOG)
Broadcom (AVGO)
Berkshire Hathaway Inc-cl B Cl B New (BRK.B)
Tesla Motors (TSLA)
Eli Lilly & Co. (LLY)
JPMorgan Chase & Co. (JPM)
UnitedHealth (UNH)
Exxon Mobil Corporation (XOM)
Visa Inc-class A Shares Com Cl A (V)

View all positions for Geode Capital Management

Top funds holding Rapport Therapeutics

Arch Venture Corp
Cormorant Asset Management
Capital Research and Management Company - Division 3
Johnson & Johnson
Sofinnova Ventures
T. Rowe Price Investment Management
Alliancebernstein
T. Rowe Price Associates
Perceptive Advisors
BlackRock
Citadel Advisors
Siren
Logos Global Management
Geode Capital Management
Woodline Partners

View all funds holding Rapport Therapeutics